| 9.04 0.33 (3.79%) | 11-11 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.67 | 1-year : | 14.8 |
| Resists | First : | 10.85 | Second : | 12.67 |
| Pivot price | 9.14 |
|||
| Supports | First : | 6.79 | Second : | 4.29 |
| MAs | MA(5) : | 8.67 |
MA(20) : | 8.4 |
| MA(100) : | 6.79 |
MA(250) : | 9.32  |
|
| MACD | MACD : | 0.8 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 34.2 |
D(3) : | 40.5 |
| RSI | RSI(14): 63.2 |
|||
| 52-week | High : | 17 | Low : | 2.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ REPL ] has closed below upper band by 44.7%. Bollinger Bands are 40.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.77 - 8.83 | 8.83 - 8.88 |
| Low: | 8.28 - 8.35 | 8.35 - 8.42 |
| Close: | 8.6 - 8.71 | 8.71 - 8.82 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Fri, 07 Nov 2025
Replimune Group Presents Positive Late-Breaking Data on RP1 Plus Nivolumab at SITC 2025 Conference - Quiver Quantitative
Fri, 07 Nov 2025
Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan
Thu, 23 Oct 2025
Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market? - simplywall.st
Tue, 21 Oct 2025
Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha
Tue, 21 Oct 2025
JP Morgan Upgrades Replimune Group (REPL) - Nasdaq
Mon, 20 Oct 2025
Replimune Group, Inc. (REPL) Stock: Soars 120% After FDA Accepts RP1 BLA Resubmission - parameter.io
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 104.6 (%) |
| Shares Short | 18,250 (K) |
| Shares Short P.Month | 17,280 (K) |
| EPS | -3.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.5 % |
| Return on Equity (ttm) | -73.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -220 (M) |
| Levered Free Cash Flow | -130 (M) |
| PE Ratio | -2.87 |
| PEG Ratio | 0 |
| Price to Book value | 2.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|